McParland C, Cotton D J, Gowda K S, Hoeppner V H, Martin W T, Weckworth P F
Department of Medicine, University of Saskatchewan, Saskatoon, Canada.
Am Rev Respir Dis. 1992 Nov;146(5 Pt 1):1330-3. doi: 10.1164/ajrccm/146.5_Pt_1.1330.
Intravesical instillation of bacille Calmette-Guérin (BCG), an attenuated strain of Mycobacterium bovis, is the treatment of choice for many patients with bladder cancer. In a small percentage, this therapy is associated with systemic side effects including pneumonitis. It is uncertain whether these systemic manifestations are due to dissemination of infection or due to hypersensitivity, an etiologic distinction that has important therapeutic implications. We report the first case in which miliary M. bovis was proven to be the responsible mechanism, by culture of M. bovis biovar BCG from a transbronchial lung biopsy and complete resolution on anti-tuberculous chemotherapy.
膀胱内灌注卡介苗(BCG),一种减毒的牛分枝杆菌菌株,是许多膀胱癌患者的首选治疗方法。在一小部分患者中,这种治疗会伴有包括肺炎在内的全身副作用。目前尚不清楚这些全身表现是由于感染播散还是由于超敏反应所致,这种病因学上的区分具有重要的治疗意义。我们报告了首例经证实粟粒性牛分枝杆菌是致病机制的病例,通过经支气管肺活检培养出牛分枝杆菌卡介苗生物变种,并在抗结核化疗后完全缓解。